204 related articles for article (PubMed ID: 32034133)
1. G protein-coupled kisspeptin receptor induces metabolic reprograming and tumorigenesis in estrogen receptor-negative breast cancer.
Dragan M; Nguyen MU; Guzman S; Goertzen C; Brackstone M; Dhillo WS; Bech PR; Clarke S; Abbara A; Tuck AB; Hess DA; Pine SR; Zong WX; Wondisford FE; Su X; Babwah AV; Bhattacharya M
Cell Death Dis; 2020 Feb; 11(2):106. PubMed ID: 32034133
[TBL] [Abstract][Full Text] [Related]
2. G protein-coupled KISS1 receptor is overexpressed in triple negative breast cancer and promotes drug resistance.
Blake A; Dragan M; Tirona RG; Hardy DB; Brackstone M; Tuck AB; Babwah AV; Bhattacharya M
Sci Rep; 2017 Apr; 7():46525. PubMed ID: 28422142
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of fatty acid oxidation as a therapy for MYC-overexpressing triple-negative breast cancer.
Camarda R; Zhou AY; Kohnz RA; Balakrishnan S; Mahieu C; Anderton B; Eyob H; Kajimura S; Tward A; Krings G; Nomura DK; Goga A
Nat Med; 2016 Apr; 22(4):427-32. PubMed ID: 26950360
[TBL] [Abstract][Full Text] [Related]
4. Profilin 2 (PFN2) promotes the proliferation, migration, invasion and epithelial-to-mesenchymal transition of triple negative breast cancer cells.
Ling Y; Cao Q; Liu Y; Zhao J; Zhao Y; Li K; Chen Z; Du X; Huo X; Kang H; Chen Z
Breast Cancer; 2021 Mar; 28(2):368-378. PubMed ID: 33047272
[TBL] [Abstract][Full Text] [Related]
5. The matrix protein Fibulin-3 promotes KISS1R induced triple negative breast cancer cell invasion.
Noonan MM; Dragan M; Mehta MM; Hess DA; Brackstone M; Tuck AB; Viswakarma N; Rana A; Babwah AV; Wondisford FE; Bhattacharya M
Oncotarget; 2018 Jul; 9(53):30034-30052. PubMed ID: 30046386
[TBL] [Abstract][Full Text] [Related]
6. Knockdown of endothelin receptor B inhibits the progression of triple-negative breast cancer.
Gu X; Han S; Cui M; Xue J; Ai L; Sun L; Zhu X; Wang Y; Liu C
Ann N Y Acad Sci; 2019 Jul; 1448(1):5-18. PubMed ID: 30900271
[TBL] [Abstract][Full Text] [Related]
7. Silibinin induces metabolic crisis in triple-negative breast cancer cells by modulating EGFR-MYC-TXNIP axis: potential therapeutic implications.
Iqbal MA; Chattopadhyay S; Siddiqui FA; Ur Rehman A; Siddiqui S; Prakasam G; Khan A; Sultana S; Bamezai RN
FEBS J; 2021 Jan; 288(2):471-485. PubMed ID: 32356386
[TBL] [Abstract][Full Text] [Related]
8. Tumor suppressor NDRG2 inhibits glycolysis and glutaminolysis in colorectal cancer cells by repressing c-Myc expression.
Xu X; Li J; Sun X; Guo Y; Chu D; Wei L; Li X; Yang G; Liu X; Yao L; Zhang J; Shen L
Oncotarget; 2015 Sep; 6(28):26161-76. PubMed ID: 26317652
[TBL] [Abstract][Full Text] [Related]
9. Long non-coding RNA ANRIL promotes carcinogenesis via sponging miR-199a in triple-negative breast cancer.
Xu ST; Xu JH; Zheng ZR; Zhao QQ; Zeng XS; Cheng SX; Liang YH; Hu QF
Biomed Pharmacother; 2017 Dec; 96():14-21. PubMed ID: 28961506
[TBL] [Abstract][Full Text] [Related]
10. Lack of Oestrogen Receptor Expression in Breast Cancer Cells Does Not Correlate with Kisspeptin Signalling and Migration.
Azubuike UF; Newton CL; van den Bout I
Int J Mol Sci; 2022 Aug; 23(15):. PubMed ID: 35955878
[TBL] [Abstract][Full Text] [Related]
11. PKCλ/ι signaling promotes triple-negative breast cancer growth and metastasis.
Paul A; Gunewardena S; Stecklein SR; Saha B; Parelkar N; Danley M; Rajendran G; Home P; Ray S; Jokar I; Vielhauer GA; Jensen RA; Tawfik O; Paul S
Cell Death Differ; 2014 Sep; 21(9):1469-81. PubMed ID: 24786829
[TBL] [Abstract][Full Text] [Related]
12. SPAG5 upregulation contributes to enhanced c-MYC transcriptional activity via interaction with c-MYC binding protein in triple-negative breast cancer.
Li M; Li A; Zhou S; Lv H; Yang W
J Hematol Oncol; 2019 Feb; 12(1):14. PubMed ID: 30736840
[TBL] [Abstract][Full Text] [Related]
13. The circRNA circSEPT9 mediated by E2F1 and EIF4A3 facilitates the carcinogenesis and development of triple-negative breast cancer.
Zheng X; Huang M; Xing L; Yang R; Wang X; Jiang R; Zhang L; Chen J
Mol Cancer; 2020 Apr; 19(1):73. PubMed ID: 32264877
[TBL] [Abstract][Full Text] [Related]
14. Inverse Correlation of KISS1 and KISS1R Expression in Triple-negative Breast Carcinomas from African American Women.
Qasim M; Ricks-Santi LJ; Naab TJ; Rajack F; Beyene D; Abbas M; Kassim OO; Copeland RL; Kanaan Y
Cancer Genomics Proteomics; 2022; 19(6):673-682. PubMed ID: 36316037
[TBL] [Abstract][Full Text] [Related]
15. PDSS1-Mediated Activation of CAMK2A-STAT3 Signaling Promotes Metastasis in Triple-Negative Breast Cancer.
Yu TJ; Liu YY; Li XG; Lian B; Lu XX; Jin X; Shao ZM; Hu X; Di GH; Jiang YZ
Cancer Res; 2021 Nov; 81(21):5491-5505. PubMed ID: 34408002
[TBL] [Abstract][Full Text] [Related]
16. LRPPRC promotes glycolysis by stabilising LDHA mRNA and its knockdown plus glutamine inhibitor induces synthetic lethality via m
Yu Y; Deng H; Wang W; Xiao S; Zheng R; Lv L; Wang H; Chen J; Zhang B
Clin Transl Med; 2024 Feb; 14(2):e1583. PubMed ID: 38372449
[TBL] [Abstract][Full Text] [Related]
17. ANP32E induces tumorigenesis of triple-negative breast cancer cells by upregulating E2F1.
Xiong Z; Ye L; Zhenyu H; Li F; Xiong Y; Lin C; Wu X; Deng G; Shi W; Song L; Yuan Z; Wang X
Mol Oncol; 2018 Jun; 12(6):896-912. PubMed ID: 29633513
[TBL] [Abstract][Full Text] [Related]
18. Integrated Metabolic Profiling and Transcriptional Analysis Reveals Therapeutic Modalities for Targeting Rapidly Proliferating Breast Cancers.
Liao C; Glodowski CR; Fan C; Liu J; Mott KR; Kaushik A; Vu H; Locasale JW; McBrayer SK; DeBerardinis RJ; Perou CM; Zhang Q
Cancer Res; 2022 Feb; 82(4):665-680. PubMed ID: 34911787
[TBL] [Abstract][Full Text] [Related]
19. MicroRNA 603 acts as a tumor suppressor and inhibits triple-negative breast cancer tumorigenesis by targeting elongation factor 2 kinase.
Bayraktar R; Pichler M; Kanlikilicer P; Ivan C; Bayraktar E; Kahraman N; Aslan B; Oguztuzun S; Ulasli M; Arslan A; Calin G; Lopez-Berestein G; Ozpolat B
Oncotarget; 2017 Feb; 8(7):11641-11658. PubMed ID: 28036267
[TBL] [Abstract][Full Text] [Related]
20. Glutaminase is essential for the growth of triple-negative breast cancer cells with a deregulated glutamine metabolism pathway and its suppression synergizes with mTOR inhibition.
Lampa M; Arlt H; He T; Ospina B; Reeves J; Zhang B; Murtie J; Deng G; Barberis C; Hoffmann D; Cheng H; Pollard J; Winter C; Richon V; Garcia-Escheverria C; Adrian F; Wiederschain D; Srinivasan L
PLoS One; 2017; 12(9):e0185092. PubMed ID: 28950000
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
